Datapoint: Idorsia’s Quviviq Approved for Insomnia

The FDA on Monday approved Idorsia Ltd’s Quviviq for the treatment of adults with insomnia. The dual orexin receptor antagonist (DORA) will have to face off against Merck’s Belsomra and Eisai Co.’s Dayvigo, two leading DORAs in the insomnia market basket. Belsomra currently holds covered or better status for 87% of all insured lives under the pharmacy benefit, compared to Dayvigo’s 65%.

SOURCE: MMIT Analytics, as of 1/12/2022

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 29

Datapoint: FDA Approves Latest Humira Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 28

Datapoint: Xolair Scores FDA Nod for Food Allergies

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 27

Datapoint: Aetna Sees Strong MA Growth

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today